Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) generates frequent news related to its development of immuno-pharma therapeutics, particularly its flagship product candidate Ampligen (rintatolimod). Company announcements emphasize research and development in cancers, viral diseases, immune-deficiency disorders, and cancers with unmet medical needs, as well as updates on its intellectual property portfolio and corporate actions.
News coverage for AIM ImmunoTech often focuses on clinical and scientific milestones. Recent communications describe progress in the DURIPANC clinical program, where Ampligen is evaluated in combination with AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer, and presentations of data from a completed Phase 2 study in advanced recurrent ovarian cancer combining Ampligen with cisplatin and Merck’s Keytruda (pembrolizumab). The company also highlights publications in peer-reviewed journals and abstracts accepted at major scientific meetings such as the Society for Immunotherapy of Cancer (SITC).
Another recurring theme in AIM’s news is the expansion of its intellectual property. The company has announced a European patent covering compositions of its proprietary dsRNAs, including Ampligen, for treating Long COVID, and a patent in Japan for using Ampligen with checkpoint inhibitors for cancer treatment. These updates are presented as part of AIM’s strategy to strengthen protection around Ampligen in oncology and post‑COVID indications.
Investors following AIM ImmunoTech’s news will also see items on financial and corporate developments, including stock dividends, participation in investor conferences, public offerings of common stock and warrants, and financing agreements such as a promissory note with an institutional investor. Regular news releases on quarterly financial results, capital-raising transactions, and shareholder meetings provide additional context on the company’s operations and governance.
This news page aggregates such announcements so readers can review AIM ImmunoTech’s clinical updates, patent developments, financing activities, and corporate communications in one place.
AIM ImmunoTech has commenced its Phase 1 clinical trial to evaluate the safety of Ampligen as an intranasal therapy for COVID-19 and other respiratory viral diseases. Conducted by the Centre for Human Drug Research in the Netherlands, the study will involve 40 healthy subjects. Positive preliminary in vitro results indicate that Ampligen can decrease SARS-CoV-2 viral yields by 90%. CEO Thomas K. Equels expressed optimism about Ampligen's potential in preventing COVID-19 transmission.
AIM ImmunoTech Inc. (NYSE American: AIM) announced that CEO Thomas K. Equels will present at the H.C. Wainwright Life Sciences Conference, taking place virtually on March 9-10, 2021. The presentation will be available on-demand starting March 9 at 7:00 AM Eastern Time. Registered attendees can access the webcast through the conference platform or the investor relations section of AIM's website. Additionally, management will engage in one-on-one meetings with qualified investors attending the event.
AIM ImmunoTech has received formal notification from the European Commission approving its Orphan Medicinal Product Application for Ampligen, aimed at treating pancreatic cancer. This designation grants AIM up to ten years of market exclusivity in the EU. Ampligen is expected to be a significant treatment option, with potential survival benefits demonstrated in trials. The company is currently pursuing further studies and FDA fast-track status to expedite its clinical development.
AIM ImmunoTech Inc. (NYSE American: AIM) has received Ethics Committee approval in the Netherlands for its Phase 1 clinical study of Ampligen as an intranasal therapy for COVID-19 and respiratory viral diseases. The study will enroll 40 healthy subjects to evaluate safety and tolerability over 13 days. CEO Thomas K. Equels expressed optimism about the potential of Ampligen, noting previous results that showed a 90% reduction in SARS-CoV-2 infection in vitro. Enrollment is expected to start in Q1 2021.
AIM ImmunoTech has received approval from the Dutch Health and Youth Care Inspectorate for a new Early Access Program to treat pancreatic cancer patients with rintatolimod (Ampligen) at Erasmus Medical Center. The initiative follows the success of a prior program, which demonstrated a significant survival benefit. Up to 16 patients will be treated, and the program aims to enhance patient selection. AIM plans to advance to clinical trials in the EU and U.S., seeking Fast Track status to expedite approval. The orphan drug designation offers ten years of market protection.
AIM ImmunoTech Inc. (AIM) has completed its At-The-Market (ATM) facility and closed its Equity Distribution Agreement (EDA). The company asserts it has sufficient funds to support its operational needs and clinical trials for the next 24 months. AIM plans to independently finance key developmental programs in oncology, COVID-19, ME/CFS, and Long COVID, aiming for significant advancements in 2021. CEO Thomas K. Equels highlighted the company's financial stability and commitment to achieving objectives without a renewed ATM facility.
AIM ImmunoTech has partnered with the Centre for Human Drug Research to conduct a clinical study on its Ampligen drug as an intranasal therapy for COVID-19. The study, titled "A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen," will enroll 40 healthy subjects and is fully funded by AIM. Results may provide crucial insights into the potential of Ampligen as a COVID-19 treatment, though future success is uncertain and dependent on many factors.
AIM ImmunoTech has rescheduled its investor conference call for January 21, 2021, at 11:00 a.m. ET. The call will focus on the amended AMP-511 trial treating patients with COVID-19-induced chronic fatigue symptoms, recent achievements, and future milestones. Interested parties can submit questions to management before the call. The conference will be accessible on AIM ImmunoTech's website, and a replay will be available for 90 days post-call. AIM is committed to developing therapeutics targeting various cancers, immune disorders, and viral diseases, including COVID-19.
AIM ImmunoTech Inc. (NYSE American: AIM) has announced the postponement of its upcoming investor conference call due to the recent passing of CEO Thomas K. Equels' mother. The company remains committed to its focus on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. The new date for the investor call will be communicated later.
AIM ImmunoTech has initiated the dosing of its first COVID-19 'Long Hauler' patient in the AMP-511 Expanded Access Program (EAP) with Ampligen (rintatolimod). This program addresses chronic post-COVID-19 symptoms. AIM plans to host a conference call on January 12, 2021, to update on this trial and their ongoing advancements. The EAP will enroll up to 100 participants suffering from Chronic Fatigue Syndrome, including 20 Long Haulers. AIM's CEO emphasized the urgency of developing effective therapies for these long-term COVID effects, highlighting Ampligen’s potential.